Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
51 hedge funds and large institutions have $43.8M invested in Clearside Biomedical in 2021 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 18 increasing their positions, 5 reducing their positions, and 7 closing their positions.
260% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 5
143% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 7
27% more call options, than puts
Call options by funds: $556K | Put options by funds: $437K
21% more funds holding
Funds holding: 42 → 51 (+9)
12% more capital invested
Capital invested by funds: $39.1M → $43.8M (+$4.74M)
0.09% more ownership
Funds ownership: 1.97% → 2.06% (+0.09%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$2.02M |
| 2 |
Two Sigma Investments
New York
|
+$1.92M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$1.22M |
| 4 |
Morgan Stanley
New York
|
+$1.19M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$1.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFG
Oxford Financial Group
Carmel,
Indiana
|
-$252K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$246K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$164K |
| 4 |
TFS
TrustCore Financial Services
Brentwood,
Tennessee
|
-$74K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$49.1K |
CLSD Hedge Fund Activity: Q1 2021 in Review
51 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q1 2021, worth a combined $43.8M — up 12% from $39.1M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new CLSD positions and 7 closed out — a net gain of 10 holders — while 18 added to existing stakes and 5 trimmed.
The largest buyer was Two Sigma Advisers, adding an estimated $2.02M. The largest seller was Oxford Financial Group, exiting entirely with an estimated $252K sold.
- 51 institutional investors held Clearside Biomedical (CLSD) as of Q1 2021, up from 42 in Q4 2020.
- Funds reported $43.8M of Clearside Biomedical stock for Q1 2021, up 12% quarter-over-quarter.
- 17 funds opened new Clearside Biomedical positions in Q1 2021 and 7 closed out, a net change of +10 holders.
- The largest Clearside Biomedical buyer in Q1 2021 was Two Sigma Advisers, an estimated $2.02M added.
- The largest Clearside Biomedical seller in Q1 2021 was Oxford Financial Group, an estimated $252K sold.
Based on aggregated 13F filings for Q1 2021.